Status:
COMPLETED
Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients
Lead Sponsor:
AstraZeneca
Conditions:
Borderline Personality Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
In patients with schizophrenia, 'atypical' antipsychotics such as clozapine may be effective in the treatment of psychosis. In patients with borderline personality disorder (BPD), as far as the invest...
Eligibility Criteria
Inclusion
- Patients with BPD according to Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV)/Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) including criterion 9: transient, stress related paranoid ideation or severe dissociative symptoms.
- In- or outpatients
Exclusion
- Depressive disorder
- Bipolar disorder
- Schizoaffective disorder/schizophrenia/delusional disorder/schizotypal personality disorder
- Alcohol- or substance dependence
- Quetiapine doses \>100mg od use in the past
- Somatic:
- History of trauma capitis
- Visual and auditive disorders
- Neurological disorders (epilepsy)
- Pregnancy
- No adequate contraception
- History of cardial complaints/cardiological disorder
- Known sensitivity for quetiapine
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00254748
Start Date
June 1 2004
End Date
June 1 2007
Last Update
June 11 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Apeldoorn, Netherlands
2
Research Site
Nijmegen, Netherlands
3
Research Site
Veghel, Netherlands